Interaction Checker

Interacciones de Roflumilast

Roflumilast (Daliresp), inhibidor de la PDE4, tiene 108 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 53; moderadas: 54; leves: 1; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (53)

  • AclidinioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • AdrenalinasimpaticomiméticoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • AminofilinametilxantinaGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Aprepitantinhibidor de CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Arformoterolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Armodafiniloestimulante del SNCGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • CarbamazepinaanticonvulsivoGrave

    Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • ClobazambenzodiazepinaGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Deferasiroxsuplemento de hierroGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • DexametasonacorticosteroideGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • EfavirenzantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • EslicarbazepinaanticonvulsivoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • EtravirinaantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • FenitoínaanticonvulsivoGrave

    Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Fentermina y topiramatoestimulante del SNCGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Formoterolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • FosfenitoínaanticonvulsivoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • GriseofulvinaantifúngicoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • IpratropioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Ipratropio y salbutamolanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Isoprenalina (isoproterenol)agonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Levosalbutamolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Lopinavir y ritonavirantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Lorlatinibinductor de CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Mirabegrónagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Mitapivatinductor de CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Mitotanoinductor de CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Modafiniloestimulante del SNCGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • NevirapinaantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • OxcarbazepinaanticonvulsivoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • PrimidonaanticonvulsivoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • RifabutinaantibióticoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • RifampicinaantibióticoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • RifapentinaantibióticoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • RitonavirantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Salbutamolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Salmeterolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Suzetriginainductor de CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • TeofilinametilxantinaGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Terbutalinaagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • TiotropioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • TopiramatoanticonvulsivoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (etiqueta de Roflumilast, Advertencias y precauciones)

  • UmeclidinioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Umeclidinio y vilanterolanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

  • Vibegrónagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

Interacciones moderadas (54)

  • AmiodaronaantiarrítmicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • AtazanavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • DarunavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • EstradiolestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Estrógenos conjugadosestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Estrógenos conjugados y bazedoxifenoestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Estrógenos esterificados y metiltestosteronaestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Etonogestrel y etinilestradiolestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • FluvoxaminaISRSModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • FosamprenavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • FulvestrantestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • IsoniazidaantibióticoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • LenacapavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • LevonorgestrelprogestágenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • MedroxiprogesteronaprogestágenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • MegestrolprogestágenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Norelgestromina y etinilestradiolestrógenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • NoretisteronaprogestágenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • PerampanelanticonvulsivoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • ProgesteronaprogestágenoModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (etiqueta de Roflumilast, Interacciones medicamentosas)

Menciones leves (1)

  • RiociguatvasodilatadorLeve

    Clinical experience with co-administration of Adempas and other phosphodiesterase inhibitors (for example, milrinone, cilostazole, roflumilast) is limited. (etiqueta de Riociguat, Interacciones medicamentosas)

Compruebe Roflumilast frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.